CRBU Q2 2024 Earnings — Caribou Biosciences, Inc. Revenue & Financial Results | Market Cap Arena

CRBUCaribou Biosciences, Inc.

$186M

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3M-7.7% YoY

Gross Profit

$3M75.3% margin

Operating Income

-$44M-1255.8% margin

Net Income

-$38M-1088.3% margin

EPS (Diluted)

$-0.42

QoQ Revenue Growth

+42.6%

Cash Flow

Operating Cash Flow

-$33M

Free Cash Flow

-$35M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$373M

Total Liabilities

$62M

Stockholders' Equity

$310M

Cash & Equivalents

$38M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$4M	-7.7%
Gross Profit	$3M	-$23M	+111.5%
Operating Income	-$44M	-$33M	-32.4%
Net Income	-$38M	-$30M	-27.7%

Geographic Segments

UNITED STATES

$3M99%

Non-US

$20,0001%